Member Info for Pooka

I will be interested to see if the CEO and CFO are up to the task and reward the faith in them shown by the NEDs. Both are parties to the fanciful claims in the Prospectus so in my eyes have lost credibility and fortunate to remain in their roles. I would like to see the financial reporting and accounting functions reviewed as well as the Sales team.

Thank you Pedro. Certainly lots of smallish buy trades going through this morning.

Hope you’re right Pedro and this is an isolated case of being over enthusiastic with booking sales revenues. At least the three NEDs are now on notice to double check the accuracy of the sales figures provided by the CFO who happily avoids any public censure.

I wish I had the foresight of Pentwater Capital to sell my shares on 3 June.

Blaming client uncertainty arising from the recent SDR but perhaps it runs deeper than that. The Sales team was clearly inept and could not sell their “high impact solutions”. The clowns need to find one now.

Lombard was not a major shareholder (+3%) as at 21 March 2024 according to company’s website so this looks like a substantial one-off purchase of 5.02% of the company.

Might be helpful if the Board provided some clarity as to the timescales for building a second machine, always assuming the prototype is commercially viable.

Thanks for the explanation HeresHopin - I had overlooked the placing details at 8p. I guess the directors have taken on a degree of risk as regards the personal loans to the company.

HeresHopin - I read the RNS as confirming that the two directors had paid the company £749,276 to exercise the options and subscribe for shares that will be tradeable after 30 November. The options were free but the holders have to pay to exercise them. So looks to me like a vote of confidence.

Potential investors will probably want more clarity as to the additional funding needed to get a treatment room up and running. On past form this will be 2024 rather than H2 2023 - more placings, dilution, on the cards.

Sold out about 3 years ago with an 80% loss which with benefit of hindsight was one of my better investment decisions. Although it is rather glossed over in the RNS I would expect the directors will need to satisfy investors and suppliers that the company will overcome the claim that it has no authority to operate, otherwise the rest is pointless.

Because AAL went ex-dividend today.

……28th July?

Correction - vesting date is 1st August 2022!

C

His options don’t vest until 1st August 2020.

Just more talking……….

Year high

Lots of Buys yesterday, some significant, so perhaps the interim results due 22 September will be at the top end of or exceed expectations previously announced.

The timetable will enable Qualifying Participants to use their 2021/2022 ISA allowance for the subscription.

13.40 paid on HL platform